| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
Isotope-labeled lysophosphatidylcholine; no intrinsic receptor or enzyme agonist/antagonist activity. Endogenous lyso-PC activates G-protein-coupled receptors and modulates inflammatory and vascular signaling; it is also a substrate for lysophospholipid acyltransferases in membrane remodeling. The deuterated standard is used as an analytical surrogate for lyso-PC quantification and does not engage these receptors or enzymes.
|
|---|---|
| ln Vitro |
Drug compounds have included stable heavy isotopes of carbon, hydrogen, and other elements, mostly as quantitative tracers while the drugs were being developed. Because deuteration may have an effect on a drug's pharmacokinetics and metabolic properties, it is a cause for concern [2].
The d27-lyso-PC standard shows no measurable intrinsic bioactivity and is not used for potency screening. Endogenous 14:0 lyso-PC is a short-chain lyso-PC species with distinct physicochemical properties and potential biomarker value; the d27 form co-elutes with the analyte and corrects for extraction recovery, ionization efficiency, and matrix effects during lyso-PC quantification. |
| ln Vivo |
No intrinsic in vivo pharmacological activity has been reported for the deuterated standard. Endogenous lyso-PC is a bioactive lipid and biomarker of oxidative stress and inflammation; the d27 standard supports in vivo quantification of 14:0 lyso-PC in plasma and tissue and enables studies of phospholipase A2 activity and inflammatory lipid signaling in animal models.
|
| Enzyme Assay |
LC-MS/MS lyso-PC quantification: add 14:0 Lyso PC-d27 to the sample before lipid extraction; extract lysophospholipids with methanol or chloroform/methanol; separate on a reversed-phase C18 column; monitor the specific m/z transition of the d27 standard (e.g., [M+H]+ for the phosphocholine headgroup at m/z 184) and the corresponding unlabeled transition. Quantification is by isotope-dilution calibration using peak-area ratios.
|
| Cell Assay |
Cell-based lyso-PC profiling: culture cells under conditions that modulate phospholipase A2 activity or oxidative stress, harvest and quench metabolism, add the d27-lyso-PC standard, extract lipids, and analyze by LC-MS/MS. The method enables comparison of lyso-PC levels and acyl-chain composition across treatments.
|
| Animal Protocol |
In vivo plasma and tissue lyso-PC analysis: collect plasma or tissue, add 14:0 Lyso PC-d27 before homogenization, extract lysophospholipids, and quantify lyso-PC species by LC-MS/MS. The data are used to assess phospholipase A2 activity and inflammatory lipid signaling in vivo.
|
| References |
| CAS # |
327178-90-5
|
|---|---|
| Related CAS # |
LysoPC(14:0/0:0);20559-16-4
|
| Appearance |
White to off-white solid powder
|
| SMILES |
[2H]C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])C(OC[C@@H](O)COP(OCC[N+](C)(C)C)([O-])=O)=O
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
Ethanol: ~50 mg/mL (~101.1 mM; with ultrasonication and warming)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
